Soleno Therapeutics (NASDAQ:SLNO) Receives “Hold” Rating from TD Cowen

TD Cowen reaffirmed their hold rating on shares of Soleno Therapeutics (NASDAQ:SLNO) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $53.00 price target on the stock, down from their prior price target of $85.00.

SLNO has been the subject of a number of other reports. Wall Street Zen downgraded Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Wolfe Research reiterated a “peer perform” rating on shares of Soleno Therapeutics in a report on Tuesday. Wells Fargo & Company decreased their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $93.90.

Soleno Therapeutics Stock Up 0.2%

Shares of Soleno Therapeutics stock opened at $52.35 on Tuesday. Soleno Therapeutics has a 1 year low of $29.43 and a 1 year high of $90.32. The business has a 50-day moving average of $38.17 and a two-hundred day moving average of $47.80. The company has a market capitalization of $2.70 billion, a P/E ratio of 227.62 and a beta of -2.81. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. As a group, equities analysts predict that Soleno Therapeutics will post -3.72 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Avoro Capital Advisors LLC boosted its position in Soleno Therapeutics by 12.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock valued at $134,270,000 after purchasing an additional 322,223 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Soleno Therapeutics during the fourth quarter valued at approximately $38,000. Seven Fleet Capital Management LP acquired a new position in Soleno Therapeutics during the fourth quarter valued at approximately $6,023,000. Virtu Financial LLC acquired a new position in Soleno Therapeutics during the fourth quarter valued at approximately $1,059,000. Finally, Empowered Funds LLC acquired a new position in Soleno Therapeutics during the fourth quarter valued at approximately $69,000. 97.42% of the stock is currently owned by institutional investors.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for $53.00 per share in cash (about $2.9B), giving SLNO shareholders an immediate cash premium and a clear near‑term exit/liquidity event. Read More.
• Neutral Sentiment: Some research shops have set conservative near‑term views (reaffirmations / “peer perform” ratings) as the deal closes and integration risk becomes the focus; these are neutral for deal economics but can mute momentum. Read More.
• Negative Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT™ XR, citing the acquirer’s plan to sharpen focus on the U.S. market — this reduces near‑term international upside and could lower future revenue projections for the combined company. Read More.
• Negative Sentiment: Dozens of law firms have filed or are soliciting plaintiffs in securities class actions tied to Soleno’s 2025 DCCR/VYKAT XR trial/launch setbacks; litigation risk could create damages exposure, distraction and potential deal complications. Read More.
• Negative Sentiment: Multiple firms are investigating whether the $53/share deal is fair to public shareholders and several analysts have downgraded or cut targets — these actions can pressure the stock and may prompt negotiation or litigation over price. Read More.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.